SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006138
Filing Date
2021-05-06
Accepted
2021-05-06 12:58:47
Documents
61
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20210331x10q.htm 10-Q 602538
2 EX-10.1 anvs-20210331ex1010449f2.htm EX-10.1 261124
3 EX-31.1 anvs-20210331ex311161025.htm EX-31.1 13666
4 EX-31.2 anvs-20210331ex3124a105d.htm EX-31.2 13700
5 EX-32.1 anvs-20210331ex32142a10b.htm EX-32.1 5735
6 EX-32.2 anvs-20210331ex322ec3f51.htm EX-32.2 5721
7 GRAPHIC anvs-20210331ex1010449f2001.jpg GRAPHIC 5462
  Complete submission text file 0001558370-21-006138.txt   3157799

Data Files

Seq Description Document Type Size
8 EX-101.INS anvs-20210331.xml EX-101.INS 414794
9 EX-101.SCH anvs-20210331.xsd EX-101.SCH 38667
10 EX-101.CAL anvs-20210331_cal.xml EX-101.CAL 24931
11 EX-101.DEF anvs-20210331_def.xml EX-101.DEF 103031
12 EX-101.LAB anvs-20210331_lab.xml EX-101.LAB 294826
13 EX-101.PRE anvs-20210331_pre.xml EX-101.PRE 214995
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 21896839
SIC: 2834 Pharmaceutical Preparations